Analysis of the mRNA expression of SLC2A3 in 33 different types of cancers showed that SLC2A3 was upregulated in six cancer types, including cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), and stomach adenocarcinoma (STAD) compared to normal tissues (Figure 1(a)). This evidence concerns the gene SLC2A3 and cholangiocarcinoma.